A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma

NCT04813354 PHASE4 COMPLETED Results posted

This study aims to provide data in adult participants with mild to moderate asthma to assist healthcare professionals (HCPs) in assessing various attributes of ELLIPTA and BREEZHALER DPIs, by comparing the incidence of critical and overall errors, participant preference, willingness to continue with the inhaler and time to correct use. ELLIPTA® is a registered trademark of GlaxoSmithKline (GSK) and BREEZHALER® is a registered trademark of Novartis.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE4
Status	COMPLETED
Enrolment	114
Start date	Wed Apr 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jul 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Asthma

Interventions

• ELLIPTA
• BREEZHALER

Countries

Netherlands